InMed Pharmaceuticals (INM) Net Margin (2021 - 2025)
Historic Net Margin for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to 247.29%.
- InMed Pharmaceuticals' Net Margin fell 156600.0% to 247.29% in Q4 2025 from the same period last year, while for Dec 2025 it was 170.07%, marking a year-over-year decrease of 64500.0%. This contributed to the annual value of 165.14% for FY2025, which is 18000.0% up from last year.
- Per InMed Pharmaceuticals' latest filing, its Net Margin stood at 247.29% for Q4 2025, which was down 156600.0% from 154.17% recorded in Q3 2025.
- In the past 5 years, InMed Pharmaceuticals' Net Margin registered a high of 14.56% during Q2 2023, and its lowest value of 1615.6% during Q4 2021.
- Moreover, its 5-year median value for Net Margin was 193.09% (2023), whereas its average is 457.91%.
- In the last 5 years, InMed Pharmaceuticals' Net Margin soared by 15143100bps in 2023 and then plummeted by -1359000bps in 2024.
- InMed Pharmaceuticals' Net Margin (Quarter) stood at 1615.6% in 2021, then surged by 72bps to 446.61% in 2022, then soared by 73bps to 119.19% in 2023, then crashed by -94bps to 231.63% in 2024, then dropped by -7bps to 247.29% in 2025.
- Its Net Margin was 247.29% in Q4 2025, compared to 154.17% in Q3 2025 and 137.07% in Q2 2025.